English
This article is from South Asian Journal of Cancer , volume 3 . Abstract Background:: The efficacy and safety of using combination chemotherapy with cetuximab as first-line treatment in patients with K-ras wild-type colorectal cancers has been well established. In general, weekly cetuximab was given with biweekly chemotherapy FOLFOX-4 or FOLFIRI, synchronizing them would be appealed to both patients and health care professionals. Materials and Methods:: This Phase II, prospective study investigated the efficacy and safety of using biweekly cetuximab 500 mg/m2 with chemotherapy FOLFOX-4 or FOLFIRI as first-line treatment for Chinese patients with K-ras wild-type metastatic colorectal cancer. The study endpoints included overall objective response (OR), progression-free survival (PFS), overall survival (OS) and safety. Results:: Total 15 Chinese patients (male: 10 [67%]; median age: 60 [range 41-80]) were enrolled. Patients received median 12 cycles (range 2-12) of chemotherapy + cetuximab (FOLFOX-4 + cetuximab: 9 [60%]; FOLFIRI + cetuximab: 6 [40%]). Six patients (40%) with non-progressive disease after 12 cycles of chemotherapy + cetuximab carried on maintenance cetuximab. Median d
Sign in with your free account to read, download EPUBs or listen.
Ebook · Biweekly cetuximab and first-line chemotherapy in chinese patients with k-ras wild-type colorectal cancers. · Chan, Wing-Lok, Lee, Victor Ho Fun, Siu, Wai Kwan Steven, Ho, Pui Ying Patty, Liu, Rico King Yin, Leung, To Wai · Internet Archive